Professional
Added to YB: 2024-12-13
Pitch date: 2024-09-30
NVO [bullish]
Novo Nordisk A/S
-56.91%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 116.46
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
PGIM Jennison Health Sciences Fund Portfolio Holding: Novo Nordisk A/S
NVO: Best-in-class GLP-1 portfolio driving accelerating growth in diabetes & obesity. Underappreciated magnitude & durability of new product inflection. Top 2 fastest-growing biopharma globally. Promising pipeline in NASH & Alzheimer's. 2024 sales guidance raised. Obesity market estimates likely to rise. CagriSema Phase 3 & supply ramp catalysts.
Read full article (2 min)